Essa’s shares tank as it looks for options after abandoning prostate cancer drug
Essa Pharma is exploring “strategic options” as it ends work on its prostate cancer drug that failed a mid-stage test. The company’s shares $EPIX nosedived …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
